Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » PCR » Ubiquitome Turns to Crowdfunding to Develop, Validate Zika MDx for Potential EUA

Ubiquitome Turns to Crowdfunding to Develop, Validate Zika MDx for Potential EUA

Mar 21, 2016
|
Madeleine Johnson
Premium

NEW YORK (GenomeWeb) – Ubiquitome has launched a crowdfunding campaign to support the development and validation of a molecular test for the Zika virus, with the goal of obtaining Emergency Use Authorization from the US Food and Drug Administration prior to the Olympic Games in Brazil this summer.

The New Zealand-based firm currently markets the Freedom4, a portable, battery-operated and iPhone-interfaced qPCR platform that can run four samples at a time.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

And Maybe Not

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Now Onto a Hungry Caterpillar

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

This Variant Here

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

Nature Papers Present Tool for Topological Analysis of Chromosomes, Map of Genome-Lipid Associations

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
01
Featured Webinar

Immune Repertoire Sequencing to Uncover SARS-CoV-2-Specific T Cell Responses and Dynamics

Sponsored by
Adaptive Biotechnologies

T cells are the adaptive immune system’s first responders to any virus, circulating in the blood to detect and quickly multiply to attack the virus, and also support the development of antibodies by B cells. 

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

What's Popular?

In PCR

  1. BGI Genomics Gets CE Mark for Multiplexed SARS-CoV-2, Influenza Tests

  2. FDA Grants Emergency Use Authorizations for Quadrant Biosciences, KimForest Coronavirus Tests

  3. Vela Diagnostics Receives Second FDA Emergency Use Authorization for SARS-CoV-2 Molecular Test

  4. Centogene Reports 13 Percent Decline in Q2 Revenues

  5. Becton Dickinson Submits Premarket Approval Supplement to FDA for HPV Assay

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.